As part of its efforts to normalize relations with Cuba, the U.S. has decided to allow joint medical research projects between the two countries.
it was lost in the initial news about the lessening of restrictions on Cuban
cigars and rum, the Oct. 14
House announcement said the Treasury Department's Office
of Foreign Assets Control (OFAC) will permit approval of Cuban-created
pharmaceuticals by the Food and Drug Administration and will allow them to be
imported for marketing, sale and distribution. OFAC will also allow individuals
subject to U.S. jurisdictions to engage in joint medical research projects with
In August, I wrote a special report for Bloomberg BNA and blogged about how the U.S. embargo of Cuba remains in place and that that will be the case unless there is congressional action to remove it. Meanwhile, biopharmaceutical advances created in Cuba have been mostly out of the reach of U.S. companies unless the companies have gone through what has been a fairly long process of obtaining an OFAC license.
Some promising collaborations are in the works in the areas of cancer and diabetes treatments. But investors have been hesitant to put money into projects that would be hampered by regulatory delay.
The White House’s action is the necessary next step. My article on this new initiative provides more details about the OFAC changes that were put in place.
was the next step, but not all that some had hoped for. The non
group MEDICC (Medical Education Cooperation with Cuba) sent me an e-mail noting
that the two presidential actions were top priorities in MEDICC’s white
paper that was sent to the
White House in February.
But others of its recommendations have not yet been adopted, MEDICC stated, “such as allowing U.S. patients to travel to Cuba for medical treatment, providing Americans with more options for care, especially given Cuba’s global recognition for many medical advances not yet available in the United States.”
everyone agrees with the thawing of U.S.-Cuba relations. But even the opponents
of the changes don’t want those in need to be deprived of life
and life-changing treatments.
The normalization of U.S.-Cuba relations related to medical research is proceeding step by step by step.
Stay on top of new developments in health law and regulation with a free trial to the Health Law Resource Center.
Learn more about Bloomberg Law and sign up for a free trial.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)